NASDAQ:DRRX DURECT (DRRX) Stock Price, News & Analysis $0.69 -0.01 (-1.20%) As of 01:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About DURECT Stock (NASDAQ:DRRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DURECT alerts:Sign Up Key Stats Today's Range$0.67▼$0.7150-Day Range$0.70▼$0.8652-Week Range$0.67▼$1.88Volume22,134 shsAverage Volume53,772 shsMarket Capitalization$21.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Read More… DURECT Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreDRRX MarketRank™: DURECT scored higher than 19% of companies evaluated by MarketBeat, and ranked 886th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for DURECT.Read more about DURECT's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for DURECT are expected to decrease in the coming year, from ($0.50) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DURECT is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DURECT is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDURECT has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about DURECT's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.51% of the float of DURECT has been sold short.Short Interest Ratio / Days to CoverDURECT has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in DURECT has recently decreased by 14.66%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDURECT does not currently pay a dividend.Dividend GrowthDURECT does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.19 Percentage of Shares Shorted2.51% of the float of DURECT has been sold short.Short Interest Ratio / Days to CoverDURECT has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in DURECT has recently decreased by 14.66%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.50 News SentimentDURECT has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for DURECT this week, compared to 0 articles on an average week.MarketBeat Follows3 people have added DURECT to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, DURECT insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of DURECT is held by insiders.Percentage Held by InstitutionsOnly 28.03% of the stock of DURECT is held by institutions.Read more about DURECT's insider trading history. Receive DRRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter. Email Address DRRX Stock News HeadlinesStockNews.com Initiates Coverage on DURECT (NASDAQ:DRRX)April 20, 2025 | americanbankingnews.comOppenheimer Sticks to Its Buy Rating for Durect (DRRX)March 30, 2025 | markets.businessinsider.comTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you ready for it?April 24, 2025 | Porter & Company (Ad)Here's Why We're A Bit Worried About DURECT's (NASDAQ:DRRX) Cash Burn SituationMarch 28, 2025 | finance.yahoo.comDURECT Corporation (NASDAQ:DRRX) Q4 2024 Earnings Call TranscriptMarch 28, 2025 | msn.comDURECT outlines $20M Phase 3 trial for larsucosterol in alcohol-associated hepatitisMarch 27, 2025 | msn.comDURECT Corporation (DRRX) Q4 2024 Earnings Call TranscriptMarch 26, 2025 | seekingalpha.comDURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 26, 2025 | prnewswire.comSee More Headlines DRRX Stock Analysis - Frequently Asked Questions How have DRRX shares performed this year? DURECT's stock was trading at $0.75 at the beginning of the year. Since then, DRRX shares have decreased by 8.0% and is now trading at $0.6903. View the best growth stocks for 2025 here. How were DURECT's earnings last quarter? DURECT Co. (NASDAQ:DRRX) issued its quarterly earnings results on Wednesday, March, 26th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by $0.12. The specialty pharmaceutical company had revenue of $2.30 million for the quarter, compared to analysts' expectations of $6.91 million. DURECT had a negative net margin of 198.58% and a negative trailing twelve-month return on equity of 300.62%. Read the conference call transcript. When did DURECT's stock split? Shares of DURECT reverse split on the morning of Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of DURECT? Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DURECT own? Based on aggregate information from My MarketBeat watchlists, some other companies that DURECT investors own include CymaBay Therapeutics (CBAY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), GE Aerospace (GE), Catalyst Pharmaceuticals (CPRX) and Pfizer (PFE). Company Calendar Last Earnings3/26/2025Today4/24/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DRRX CIK1082038 Webwww.durect.com Phone(408) 777-1417Fax408-777-3577Employees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,620,000.00 Net Margins-198.58% Pretax Margin-198.62% Return on Equity-300.62% Return on Assets-65.17% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.60 Sales & Book Value Annual Sales$2.03 million Price / Sales10.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book1.38Miscellaneous Outstanding Shares31,042,000Free Float30,049,000Market Cap$21.43 million OptionableOptionable Beta0.88 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:DRRX) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Intuitive Surgical at $1.99. Nvidia at $11. Shorting Fannie Mae months before collapse. That’s this analyst’s ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.